Citations

Clear

4510 citation(s) found for "Scott, C".

Analysis of evidence in NCCN harmonized guidelines for sub-Saharan Africa.
Swartz, Scott J. , Spielman, Gwynn, Agezew, Samrawit , DeBoer, Rebecca , Xu, Mary Jue , Makupa, Glory , Jung, Kathy, Luhar, Rohan, Tewari, Pariswi, Mrema, Alita , Spielman, Gwynn, Falade, Ayo , Rugengamanzi, Eulade , Chau, Courtney A. , Jung, Kathy, Tewari, Pariswi, Loon, Katherine Van , Buckle, Geoffrey Colin

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 1510-1510

10.1200/jco.2025.43.16_suppl.1510 Get It

1510 Background: The National Comprehensive Cancer Network (NCCN) Harmonized Guidelines for Sub-Saharan Africa (SSA) have emerged as leading cancer treatment guidelines in SSA. The NCCN-SSA guidelines, derived by adapting NCCN guidelines for the SSA context, offer standardized recommendations to guide cancer care and shape policy in SSA. This study examines the evidence cited in support of the NCCN-SSA guidelines, with a focus on population characteristics and generalizability to SSA. Methods: Two reviewers independently examined the NCCN-SSA guidelines for the eight most common cancers in SSA to identify all studies cited in support of treatment/management recommendations. Study selection discrepancies were resolved by discussion. Full-text articles were reviewed and data on age, sex, race, and recruitment geography were abstracted. Descriptive analyses were performed using R statistical software. Results: Overall, 4,589 citations were reviewed, and 2,938 (64.0%) studies with individual-level data were included, representing >10.4 million study participants. Of the 2,061 studies reporting geographic information (70%), 50 (2.4%) recruited in SSA; of these, 39 (83.0%) recruited from South Africa. Three studies (0.2%) recruited exclusively in SSA. Most studies (95.3%) recruited exclusively from high or upper-middle income countries. Only 29.2% of studies with race data included >10% Black study participants. Conclusions: Most studies cited in the NCCN-SSA guidelines were conducted in high-income countries outside SSA. A small minority of all study participants were Black. Our findings underscore potential limitations in the generalizability of the NCCN-SSA guidelines to SSA and highlight a pressing need to generate and incorporate context-specific data to guide care and inform policy. WHO region of recruitment, race, and country-level income of studies included in NCCN-SSA guidelines. Cancer type # (%) studies reporting geography # (%) studies by recruitment region*: Americas # (%) studies by recruitment region*: Europe # (%) studies by recruitment region*: Sub-Sah. Africa % participants, White % participants, Black % participants, Other race # (%) studies representing only HMIC (per World Bank) Overall 2061(70%) 1177 (57%) 921 (45%) 50 (2%) 79% 9% 11% 1964(95%) B-cell 325(57%) 173 (53%) 178 (55%) 5(2%) 82% 7% 10% 307(94%) Breast 206(44%) 123 (60%) 124 (60%) 12 (6%) 80% 9% 11% 179(87%) Cervical 163(90%) 100 (61 %) 44(27%) 3(2%) 64% 14% 22% 158(97%) Colorectal 584(82%) 278 (48%) 292 (50%) 11 (2%) 80% 10% 10% 571 (98%) Hepato-cellular 183(74%) 80(44%) 68(37%) 0(0%) 69% 9% 22% 169(92 %) Kaposi sarcoma 51(80%) 25 (49%) 19(37%) 5(10%) 38% 51% 10% 44(86%) Ovarian 115(56%) 76 (66%) 35 (30%) 0(0%) 83% 4% 13% 115(100%) Prostate 434(88 %) 322 (74 %) 161 (37%) 14 (3%) 79% 9% 12% 421(97%) HMIC = high and upper-middle income countries. *Percent of studies includes as the denominator only the number of studies with reported geographies.
Interim safety and efficacy data of [ 212 Pb]VMT01 in MC1R expressing melanoma.
Block, Matthew S. , Mehr, Samuel H., Baratto, Lucia , Tomash, Haley, Yang, Wenjing , Puhlmann, Markus , Morris, Zachary Scott , Wahl, Richard L. , Marsh, Ian R. , O’Keefe, Stephen J. , Menda, Yusuf

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 3099-3099

10.1200/jco.2025.43.16_suppl.3099 Get It

3099 Background: Immune checkpoint inhibitors (ICI) are effective in melanoma, but many patients experience progression on or after approved ICI +/- MAPK inhibitor therapy. Melanocortin-1 receptor (MC1R) is a novel target for radiopharmaceutical therapy (RPT) and is highly expressed on melanoma tumor cells. VMT01 is an MC1R-targeted RPT that can be radiolabeled with either 203 Pb (patient selection and dosimetry assessments) or 212 Pb (alpha particle therapy). Here, we present data on the first in-human evaluation of [ 203 Pb/ 212 Pb]VMT01 in patients with metastatic melanoma. FDA granted Fast Track Designation to the product on the bases of preclinical experiments combining [ 212 Pb]VMT01 with immunotherapy. Methods: This is a first-in-human dose-finding study to determine the safety, pharmacokinetics, dosimetry and preliminary efficacy of [ 212 Pb]VMT01 in subjects with MC1R-positive metastatic melanoma who progressed on at least 1 approved first-line therapy (NCT05655312). Phase 1 of the trial includes escalating dose cohorts. The first two cohorts incorporate dosimetry evaluations (reported separately) with the imaging surrogate [ 203 Pb]VMT01 prior to receiving up to 3 treatment cycles of [ 212 Pb]VMT01 therapy (injected activity of 111 MBq (3 mCi) or 185 MBq (5 mCi) for Cohort 1 and 2, respectively). Participants are evaluated for any DLT for the first 6 weeks after cycle one. Efficacy is assessed by RECIST 1.1 criteria by the investigator. Following the start of the study the anticipated combination arm with nivolumab was opened as an amendment. Results: Cohort 1 (DCO 04Sep24) was completed with 3 enrolled participants who received 3 treatment cycles without any DLTs or SAEs. Cohort 1 participants showed prolonged stabilization of disease from start of treatment (mean: 11.1 months); one participant developed a confirmed objective response (PR) after completion of all three [ 212 Pb]VMT01 administrations and is still on trial after 13.1 months from start of treatment. Cohort 2 has completed with 7 enrolled participants. No DLTs or related SAEs have been observed. All participants in this Cohort progressed after either the first cycle (3 participants) or the second cycle (4 participants).Based on these preliminary results showing anti-tumor effect at the lower dose, additional cohorts for both monotherapy and in combination with nivolumab were introduced at a de-escalated dose of 55.5 MBq (1.5 mCi). Both cohorts are now open for enrollment. Updated safety and efficacy data will be analyzed and presented at ASCO. Conclusions: At 111 MBq and 185 MBq activity levels, [ 212 Pb]VMT01 was safe and well-tolerated. An objective response and prolonged stabilization of disease were observed at the 111 MBq activity level while no effect was seen at 185 MBq. The study will continue to explore potentially immunostimulating lower doses of administered activity of [ 212 Pb]VMT01 either as a monotherapy or in combination with nivolumab. Clinical trial information: NCT05655312 .
Improved detection of circulating tumor DNA in patients with leiomyosarcoma with fragment size restriction.
Ruzgar, Nensi M. , Shafer, Amanda M., Schuetze, Scott M. , Klega, Kelly S. , Ricker, Cora A. , Tanhaemami, Mohammad , Reinke, Denise K. , Siontis, Brittany L. , Crompton, Brian D.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 3046-3046

10.1200/jco.2025.43.16_suppl.3046 Get It

3046 Background: Prior work has shown that detection of circulating tumor DNA (ctDNA) at time of diagnosis of leiomyosarcoma (LMS) is associated with lower likelihood of objective response and patients with detectable ctDNA after two cycles of chemotherapy have worse survival. However, because ctDNA exists at much lower concentrations in plasma compared to cell-free DNA of non-tumor origin, the sensitivity of these prognostic measures to tumor signals remains unclear. With increasing evidence of ctDNA fragments being shorter than the background non-tumor cell-free DNA, we sought to test whether restricting our analysis to smaller fragment sizes would improve detection of ctDNA in LMS. Methods: Plasma was serially collected from patients with LMS undergoing chemotherapy. Cell-free DNA extracted from these samples was profiled by ultra-low-passage whole-genome sequencing (ULPWGS). Copy number alterations were identified and used to detect ctDNA using the ichorCNA algorithm before and after restricting the dataset to fragments of 90-150bp (short). We compared detectability of ctDNA via ichorCNA between analyses using all sequencing data and those using data restricted to short fragments. Results: From 28 patients, 126 plasma samples were profiled. The median fragment length of cell-free DNA was 240bp (IQR 142-349) for patients with LMS, compared to 307bp (IQR 171-465, p < 0.001) in samples collected from healthy controls. Short fragments made up 19.48% of LMS libraries at diagnosis when ctDNA levels were highest, 15.27% of all LMS samples, and 12.96% of libraries from healthy controls. While ctDNA was detectable by ULPWGS in 17% of all samples, detection increased to 40% when analyzed using only short cell-free DNA fragments (p < 0.0001). The proportion of diagnostic samples with detectable ctDNA was nominally higher when analyzed by short fragments (39% vs. 64% with 90-150bp size restriction, p = 0.1078, n = 28) and was significantly higher in samples collected after two cycles of chemotherapy (5% vs. 40% with 90-150bp size restriction, p = 0.0197, n = 20). Increases in ctDNA detectability with fragment size restriction were also observed in each of localized and metastatic subgroups (metastatic: 16% without restriction, 38% with restriction, n = 97, p = 0.0012; localized: 17% vs. 45%, n = 39, p = 0.04). Conclusions: Our results demonstrate that detection of ctDNA is improved by analyzing short fragments of cell-free DNA in samples collected from patients with LMS. These findings represent a potential to increase the sensitivity of an affordable, low-coverage liquid biopsy assay and may enhance the prognostic value of ctDNA detection in these patients. Further study of the association between ctDNA detection and outcome is needed to fully validate the impact of fragment size restricted analysis of cell-free DNA samples in patients with LMS and is currently ongoing in a prospective study.
Patient (pt) characteristics, treatment patterns, and outcomes in unresectable hepatocellular carcinoma (uHCC) treated with first-line (1L) systemic therapy in the United States (US).
Rangarajan, Nivedita , Purushotham, K, Nadig, Mihika, Wagner, Tyler , Valerio, Stephen J. , Anderson, Ryan T. , Olson, Jody C. , Tran, Nguyen H. , Soefje, Scott A. , Wagner, Tyler E., Anderson, Rye

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e16167 Get It

e16167 Background: Guidelines recommend systemic therapy for uHCC ineligible for locoregional therapy. Until the approval of tremelimumab + durvalumab for uHCC, in Oct 2022, 1L systemic therapies in the US included multikinase inhibitors and atezolizumab (A) + bevacizumab (B). It is crucial to understand factors driving real-world treatment decisions and outcomes in uHCC. Methods: Data were collected from electronic medical records from US Mayo Clinic sites. Pts with uHCC who initiated a 1L systemic therapy between Jun 2020–Oct 2022 (A + B was the only approved 1L immunotherapy (IO)-based regimen) with ≥2 follow-up visits, were included. Index was the date of first 1L systemic therapy. Pts were assessed by risk of post-index gastrointestinal (GI) bleeding (Child-Pugh class B or C, pre-index GI bleeding, uncontrolled hypertension [HTN] [≥2 anti-HTN drugs or ≥2 vital entries of SBP > 140 mmHg or DBP > 90 mmHg]), or significant varices and band ligation). Treatment patterns, overall survival (OS), and post-index GI bleeding were assessed. Results: A total of 186 pts met the inclusion criteria. Most common etiologies of liver disease were MASH (42.7%) and hepatitis C virus (40.2%). Pre-index GI bleeding was reported in 29.0% of pts, of which 46.3% occurred within 6 months (mo) pre-index; 62.4% of pts had EGD, of which 72.4% had varices. There were 128 (68.8%) pts with GI bleeding risk and 58 (31.2%) pts without GI bleeding risk. The most common 1L systemic therapies for pts with GI bleeding risk were A + B (72.7%) and A only (9.4%), while for pts without GI bleeding risk, A + B (29.3%), nivolumab + ipilimumab (13.8%), and B + chemotherapy (12.1%) were the most common. Median OS and OS rates at 12, 18, and 24 mo were lower, and post-index GI bleeding rate was higher in pts with vs without GI bleeding risk (Table). For pts treated with A + B, median OS and OS rates at 12, 18, and 24 mo were lower in pts with vs without GI bleeding risk (Table). Conclusions: In this network, prior to the approval of other 1L IO-based regimens for uHCC, many pts received A + B, despite risk of post-index GI bleeding. Median OS with A + B was shorter in pts with vs without GI bleeding risk. Data highlight the complexity of uHCC and the unmet need for guidance on characteristics-driven treatment decisions. © 2025 American Society of Clinical Oncology, Inc. Reused with permission. This abstract was accepted and previously presented at the 2025 ASCO Gastrointestinal Cancers Symposium. All rights reserved. Table. Full cohort A + B cohort All ptsN=186 GI bleeding risk N=128 No GI bleeding risk N=58 All pts N=110 GI bleeding risk N=93 No GI bleeding risk N=17 Median follow-up, mo 20.6 20.9 20.4 21.3 21.6 20.3 Median OS, mo 14.4 11.4 40.3 13.9 12.8 Not reached OS rates, % 12 mo 55.2 48.9 68.9 55.2 52.3 70.6 18 mo 45.3 38.1 61.1 44.1 41.6 57.8 24 mo 39.4 31.8 56.8 37.1 34.6 51.3 Post-index GI bleed, % 17.2 23.4 3.4 17.3 19.4 5.9
Evaluating pegylated SN38 (PLX38A) and rucaparib in TP53 wild-type endometrial cancer.
Brennan, Mikayla, Weroha, Saravut J., Hou, Xiaonan , Dowdy, Sean C. , Xu, Conway, Brennan, Mikayla, Kaufmann, Scott H. , Glaser, Gretchen

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e15125 Get It

e15125 Background: Endometrial cancer (EC) is the most common gynecologic malignancy, with endometrioid being the most prevalent histology. Approximately 75% of high-grade endometrioid tumors are TP53 wild-type. During studies testing a novel combination of the PARP inhibitor rucaparib and TOP1 poison SN38 in high-risk primary patient serous and serous-like ECs, a subset of non-serous ECs with normal p53 expression showed unexpected synergy. This suggests broad efficacy in EC, warranting in vivo studies to assess tolerability and efficacy. Given potential overlapping toxicity, a novel formulation, pegylated SN38 (PLX038A), was tested. Methods: Primary patient tumors (n=4) were treated with rucaparib (0µM-25 µM) and SN38 (0µM-0.5 µM) in 3D cell culture experiments. RealTime Glo assessed viability after 3-5 days of drug exposure. Combination indices were determined using the Chou-Talalay method. Tolerability and efficacy were assessed in female SCID-beige mice (n=45) injected with intraperitoneal EC PDX tumors. Mice were randomized to controls, PLX038A (15 mmol/µmol IP, every 14 days), rucaparib (150 mg/kg daily gavage), or combination (same dose and schedule) for 8 weeks. Tolerability was assessed by daily animal weight and total condition score (TCS) from 1 (emaciated, non-ambulatory) to 13 (obese). Weight change more than -20% or TCS < 5 defined moribund criteria. Weekly ultrasound measurements assessed tumor response. Results: All four primary patient tumors exhibited synergy, with a combination index less than 1. Moribund criteria were not met in any mice across all cohorts. The average percent weight change and lowest TCS across cohorts were: rucaparib (-8.51%, min/max -19 to +14%; TCS 6.25, range 5-8, n=8), PLX038A (-3.97%, min/max -19 to +5%; TCS 6.8, range 6-9, n=10), the combination (-5.52%, min/max -15 to +1.8%; TCS 7.18, range 6-8, n=11), and control (+1.61%, range -6 to +8%; TCS 6.5, range 6-7, n=4). Scores were similar between groups, but the slightly lower TCS in the rucaparib cohort was associated with higher tumor burden from ineffective therapy. Tumors in the rucaparib monotherapy group grew similarly to controls. In contrast, the combination therapy cohort exhibited significant regression below baseline during treatment. Conclusions: These findings suggest that the combination of rucaparib and SN38 (PLX038A) is effective in EC primary patient tumor organoids and PDXs with wild-type TP53. No significant negative physiological effects on animal TCS and weight change were observed. No drug-related toxicity was observed in mice receiving combination treatment. Mice receiving combination treatment displayed significant tumor regression below baseline compared to both single agents and control. These data support future exploration of this combination therapy in ECs.
Utilization of tumor-informed ctDNA to de-escalate treatment or monitoring in metastatic breast cancer exceptional responders.
Janda, Guneet, Haddad, Tufia C. , Peethambaram, Prema P. , Leon‐Ferre, Roberto A. , Calkins, Hannah, Rodriguez, Angel , Liu, Minetta C. , Goetz, Matthew P. , Scott, Nicole, Giridhar, Karthik V.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e13042 Get It

e13042 Background: The conventional treatment paradigm for metastatic breast cancer (MBC) is to continue systemic therapy until disease progression. With improved systemic therapy options, some patients (pts) with MBC attain radiographic remission. Tumor-informed circulating tumor (ct)DNA detects molecular disease burden and may guide decision-making. We report on an institutional cohort of pts with MBC in which tumor-informed ctDNA testing was utilized prospectively to guide decisions on systemic therapy or surveillance imaging frequency. Methods: Utilizing an IRB-approved protocol, we retrospectively identified pts monitored with tumor-informed ctDNA using the Signatera™ mPCR-NGS assay (Natera, Inc) as part of routine clinical care in Mayo Clinic, Rochester. We then identified a subset with biopsy-proven MBC who attained radiographic remission of disease following systemic therapy, deemed by the treating medical oncologist as “exceptional responders”. Real-time ctDNA testing was used to inform a decision to either discontinue systemic therapy, treatment de-escalation (remove a component of multi-drug therapy), increase the time interval between restaging scans, or stay off therapy previously stopped due to toxicity . Data on breast cancer characteristics, imaging results, ctDNA test results, and outcomes were collected. Descriptive statistics were used to analyze the data. Results: 10 pts met our study criteria. The median age at MBC diagnosis was 42 years (range 28-61); 5 pts had TNBC, 3 pts had HER2+, and 2 pts with ER+/HER2- MBC. Most pts (60%) were on first or second line therapy (range 1-5). The median duration of the most recent regimen was 27.5 months (range 10-70 months). All pts were without radiographic evidence of active cancer at the time of ctDNA testing with negative results (0 MTM/mL) at the time of clinical decision-making. 4 pts stopped all systemic therapy and proceeded with observation (1 trastuzumab, 1 trastuzumab deruxtecan, 1 pembrolizumab, and 1 talazoparib). 2 pts discontinued a targeted therapy (1 olaparib, 1 abemaciclib) while continuing endocrine therapy. 1 patient stopped targeted therapy (abemaciclib) due to a blood clot, and ctDNA testing guided the decision to not start another CDK4/6 inhibitor while continuing endocrine therapy. In 3 pts the frequency of restaging scans was decreased to either annually or semi-annually. The median follow-up after a ctDNA-informed decision was 11 months (range 1-41 months). At this time, no patient has converted to ctDNA-positivity, experienced resurgence or progression of disease, needed to change systemic therapy or increase imaging frequency. Conclusions: Tumor-informed ctDNA may offer additional confidence to oncologists and pts to deescalate systemic therapy or decrease the interval of imaging frequency in exceptional responders with MBC. Additional data to support this approach is needed.
A first-in-human multi-center phase 1/2 study of a selective FGFR2/3 inhibitor, CGT4859, in patients with intrahepatic cholangiocarcinomas or other advanced solid tumors.
Ellis, Haley , Ahnert, Jordi Rodon, Starodub, Alexander, Ali, Akza, Moynihan, Kevin, Little, Meredith, Zou, Liangxing, Lawrence, Julia, Vogel, Arndt, Vogel, Arndt , Vogel, Arndt , Goyal, Lipika , Borad, Mitesh J. , Kim, Richard D. , Ahnert, Jordi Rodon, Valle, Juan W. , Bridgewater, John , Russell, Jeffery Scott , Ali, Akza

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.tps3171 Get It

TPS3171 Background: Genetic alterations in fibroblast growth factor receptors 2 and 3 ( FGFR2/3 ) occur in nearly all cancer types. FGFR2 fusions and rearrangements occur in up to 10-15% of intrahepatic cholangiocarcinomas (iCCA) and alterations in FGFR3 occur in 15-30% of urothelial cancers. The clinical benefit from currently approved FGFR inhibitors (FGFRi) is often curtailed by development of acquired resistance, which may arise through on-target mutations in the FGFR2/3 kinase domain. Additionally, off-tumor effects on FGFR1 by pan-FGFRi can lead to hyperphosphatemia and consequently to dose reductions or dose holds. Thus, there is an unmet clinical need for a selective FGFR2/3 inhibitor that has clinical efficacy against activating alterations and resistance mutations without causing FGFR1-mediated hyperphosphatemia. CGT4859 is an orally bioavailable, ATP-competitive, reversible inhibitor of FGFR2/3, with potency against clinically relevant FGFR2/3 kinase domain mutations. In addition, CGT4859 demonstrates >140 fold selectivity over FGFR1, and shows robust efficacy in target altered in vivo tumor models without increases in serum phosphorus. Nonclinical pharmacokinetics (PK) and safety data support evaluating CGT4859 in a first-in-human, open-label, dose-escalation and signal-seeking Phase I/II study (NCT06777316). Safety, tolerability, PK, pharmacodynamics, and antitumor activity of CGT4859 will be assessed in adults with histologically confirmed unresectable or metastatic iCCA or other solid tumors with FGFR2/3 alterations. Methods: CGT4859 will be administered orally continuously in 28-day cycles to patients (N=~50) at a starting dose of 1 mg QD, and dose escalation will not exceed 40 mg QD as determined using a Bayesian optimal interval design with backfill (BF-BOIN). This approach will be used to guide dose escalation and establish the maximum tolerated dose (MTD) and recommended Phase 2 Dose (RP2D). BF-BOIN enables backfilling of participants to doses that are cleared for safety during the dose escalation, generating additional data on safety and tolerability below the MTD. Objective response rate (ORR) and disease control rate will be determined based on investigator assessment using RECIST v1.1. Phase II will enroll up to 4 cohorts, each enrolling ~15 patients. Proposed cohorts will include participants who have iCCA and are either FGFRi-naïve or FGFRi-exposed. Two additional cohorts with other advanced solid tumors harboring FGFR2/3 alterations may be included based on signals detected in dose escalation. The primary efficacy endpoint for Phase II is ORR per RECIST v1.1. The preclinical data support the study of CGT4859 in this patient population with solid tumors harboring FGFR2 and/or FGFR3 genetic alterations. The phase I dose escalation study is currently enrolling at sites in the United States. Clinical trial information: NCT06777316 .
Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association
Cusi, Kenneth , Bardsley, Joan K. , Isaacs, Scott , Kanwal, Fasiha , Richardson, Caroline R., Roden, Michael, Younossi, Zobair M. , Bajaj, Mandeep , Bajaj, Mandeep , Abdelmalek, Manal F. , Bannuru, Raveendhara R , Apovian, Caroline M , Balapattabi, Kirthikaa , Bannuru, Raveendhara R. , Barb, Diana , Beverly, Elizabeth Ann , Corbin, Karen D. , ElSayed, Nuha A. , Pekas, Elizabeth J. , Richardson, Caroline R., Roden, Michael , Sanyal, Arun J. , Shubrook, Jay H

Mayo Clinic

Diabetes Care | May 28, 2025 | Volume: 48 | Issue: 7 | Pages: 1057-1082

10.2337/dci24-0094 | PMID 40434108 Get It

Metabolic dysfunction–associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease (NAFLD), is a growing but often unrecognized medical problem for people with diabetes (particularly type 2 diabetes, especially when associated with obesity). Liver health has not been at the forefront of complications tracked for disease prevention, as traditionally done for diabetic retinopathy, nephropathy, or neuropathy. However, liver steatosis affects approximately two out of three people with type 2 diabetes and places them at an increased risk for metabolic dysfunction–associated steatohepatitis (MASH), cirrhosis, hepatocellular carcinoma (HCC), and overall liver-related mortality. MASLD is also associated with extrahepatic cancers, atherosclerotic cardiovascular disease, and progression from prediabetes to type 2 diabetes and negatively impacts health-related quality of life. However, most individuals and their health care professionals remain unaware of the severe hepatic or extrahepatic health risks associated with MASLD and the need for early identification. In recognition of this knowledge gap and the rising prevalence of MASLD, this consensus report is a call to action to screen for liver fibrosis and risk stratify people with prediabetes or type 2 diabetes, in particular if obesity is also present. This consensus report explains the rationale for the recent MASLD nomenclature change, how to best risk stratify, current treatment and long-term monitoring options, the value of an interprofessional approach to disease management, and the impact of alcohol intake on liver health. More awareness about the health risks associated with MASLD and broad adoption of screening for liver fibrosis as a new standard of care hold promise for a future without cirrhosis for people with prediabetes and type 2 diabetes.
Vaccination as a new form of cardiovascular prevention: a European Society of Cardiology clinical consensus statement
Heidecker, Bettina , Libby, Peter , Vassiliou, Vassilios S. , Vardeny, Orly , Hassager, Christian , Gatzoulis, Michael Α. , Metra, Marco , Amir, Offer , Solomon, Scott, Landmesser, Ulf, Lüscher, Thomas F. , Vardeny, Orly , Gatzoulis, Michael A , Mamas, Mamas , Cooper, Leslie T , Metra, Marco , Amir, Offer , Libby, Peter , Heidecker, Bettina , Hassager, Christian , Vassiliou, Vassilios , Roubille, François , Mamas, Mamas A. , Cooper, Leslie T. , Schoenrath, Felix , Landmesser, Ulf

Mayo Clinic

European Heart Journal | May 27, 2025 | Volume: 46 | Issue: 36 | Pages: 3518-3531

10.1093/eurheartj/ehaf384 | PMID 40582710 Get It

Abstract Vaccination is increasingly acknowledged as an effective preventive measure not only against specific infections, but also for the prevention of cardiovascular disease in high-risk patients. Specifically, a growing body of evidence suggests that vaccines against influenza, SARS-CoV-2, respiratory syncytial virus, herpes zoster, and other viruses significantly reduce infection and for influenza the incidence of major adverse cardiovascular events in vaccinated individuals. This clinical consensus statement examines the existing literature and accumulated evidence and offers practical clinical advice on vaccination timing and target demographics, specifically addressing complex clinical scenarios with a focus on cardiovascular conditions. It includes guidelines for vaccinating vulnerable populations such as immunosuppressed individuals, patients with congenital heart disease, and pregnant women as well as safety and potential complications of the procedure.
Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool
Hawkes, Will, Woodward, Gary , Hamza, Izhan, Desai, Viral , Barrett‐O’Keefe, Zachary , Grogan, Martha, Davison, Halley, Maurer, Mathew S. , Helmke, Stephen , Scherrer‐Crosbie, Marielle , Soltani, Marwa , Goyal, Akash , Zaręba, Karolina M. , Cheng, Richard K. , Vieira, Marcelo Luiz Campos , Elissamburu, Pablo , Ronderos, Ricardo , Prado, Aldo , Sarswat, Nitasha , Addetia, Karima , Ruberg, Frederick L. , Randazzo, Michael , Al-Roub, Nora , Kidd, Liam, Lang, Roberto M. , Pellikka, Patricia A. , Barrett-O'Keefe, Zachary, Scott, Christopher , Davison, Halley N, Cheng, Richard , Kirkpatrick, James N , Koutroumpakis, Efstratios , Deswal, Anita M , Pursnani, Amit , Pellikka, Patricia A , Slivnick, Jeremy A. , Hawkes, Will, OLIVEIRA, JORGE COELHO , Akerman, Ashley, Gómez, Alberto , Grogan, Martha , Dispenzieri, Angela , Scott, Christopher G. , Cotella, Juan Ignacio , Maurer, Mathew S , Kitano, Tetsuji , Takeuchi, Masaaki , Hotta, Viviane Tiemi , Patel, Amit R. , Asch, Federico M. , O’Driscoll, Jamie M. , Strom, Jordan B. , Kidd, Liam, Cuddy, Sarah A. M. , Upton, Ross

Mayo Clinic

European Heart Journal | May 26, 2025 | Volume: 46 | Issue: 40 | Pages: 4090-4101

10.1093/eurheartj/ehaf387 | PMID 40631729 Get It

Abstract Background and Aims Accurate differentiation of cardiac amyloidosis (CA) from phenotypic mimics remains challenging using current clinical and echocardiographic techniques. The accuracy of a novel artificial intelligence (AI) screening algorithm for echocardiography-based CA detection was assessed. Methods Utilizing a multisite, multiethnic dataset (n = 2612, 52% CA), a convolutional neural network was trained to differentiate CA from phenotypic controls using transthoracic apical four-chamber video clips. External validation was conducted globally across 18 sites including 597 CA cases and 2122 controls. Classification accuracy was assessed on the entire external validation dataset, and subgroup analyses were performed both on technetium pyrophosphate scintigraphy referrals, and individuals matched for age, sex, and wall thickness. Model accuracy was also compared with the transthyretin CA score and the increased wall thickness score within a subset of older heart failure with preserved ejection fraction patients with increased wall thickness. Results Cardiac amyloidosis patients and controls displayed similar age, sex, race, and comorbidities. After the removal of uncertain AI predictions (13%), model discrimination and classification were excellent for the entire external validation dataset [area under the receiver operating characteristic curve (AUROC) 0.93, sensitivity 85%, specificity 93%], irrespective of CA subtype (sensitivity: light-chain = 84%, wild-type transthyretin = 85%, and hereditary transthyretin = 86%). Performance was maintained in subgroup analysis in patients clinically referred for technetium pyrophosphate scintigraphy imaging (AUROC 0.86, sensitivity 77%, specificity 86%) and matched patients (AUROC 0.92, sensitivity 84%, specificity 91%). The AI model (AUROC 0.93) also outperformed transthyretin CA score (AUROC 0.73) and increased wall thickness (AUROC 0.80) scores. Conclusions This AI screening model—using only an apical four-chamber view—effectively differentiated CA from other causes of increased left ventricular wall thickness.